{"url_path":"/sec/rvrc/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-070415-index.html","accession_number":"0001213900-26-070415","cik":"0001839140","ticker":"RVRC","issuer_name":"Revium Rx.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1839140/0001213900-26-070415-index.html","primary_entity_key":"0001839140","primary_entity_name":"Revium Rx."},"word_count":255,"has_tables":true,"body_markdown":"**Item 5.02 Departure of Directors or Certain\nOfficers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.**\n\n \n\nResignation of Ms. Inna\nMartin from her positions as Director, Chief Operating Officer and President\n\n \n\nOn June 16, 2026, Ms. Inna Martin resigned from\nher position as a member of the Board of Directors of Revium Rx. (“we”, “us”, “our”, “Revium”\nor the “Company”) and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin’s resignation\nwas in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold\npositions on any committees of the Board of Directors.\n\n \n\nIn connection with Ms. Martin’s departure,\nthe Company’s subsidiary, Revium Rx Ltd. (“Revium Ltd.”) and Ms. Martin entered into a Termination Agreement and Waiver\n(the “Separation Agreement”), effective as of June 16, 2026, pursuant to which Ms. Martin’s employment and consultancy\nengagement with Revium Ltd. will terminate on September 10, 2026. Additionally, the exercise period for Ms. Martin’s vested stock\noptions to purchase up to 2,440,000 shares of the Company’s common stock has been extended until September 30, 2028. Ms. Martin’s\nshares and options are subject to certain sale restrictions as contained in the Separation Agreement.\n\n \n\n1\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**REVIUM Rx.**\n\n \n \n \n\nJune 22, 2026\nBy:\n/s/ Amir Avraham\n\n \n \nName: \nAmir Avraham\n\n \n \nTitle:\nChief Executive Officer\n\n \n\n2"}